A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies	non-small cell lung carcinoma	Recruiting	Phase 1 / Phase 2	2026-07-01		NCT05443126

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Ellipses Pharma	4

52 results · Page 1 of 3

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Assistance publique - Hôpitaux de Marseille	Marseille	France	7
Azienda Ospedaliero-Universitaria San Luigi Gonzaga	Torino	Italy	1
Centre François Baclesse	Caen	France	39
Centre Léon Bérard	Lyon	France	71
Centro di Riferimento Oncologico IRCCS	Aviano	Italy	2
Charité Comprehensive Cancer Center	Berlin	Germany	1
Cleveland Clinic Abu Dhabi (CCAD)	Abu Dhabi	United Arab Emirates	2
David Geffen School of Medicine at UCLA	Los Angeles	United States	15
Florida Cancer Specialist	Fort Myers	United States	1
Florida Cancer Specialists & Research Institute	West Palm Beach	United States	3
Fondazione IRCCS Istituto Nazionale dei Tumori	Milan	Italy	26
Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Roma	Italy	29
Georgetown University	Washington D.C.	United States	21
Guy's and St Thomas' Hospital NHSFT	London	United Kingdom	1
Hospital Madrid Sanchinarro	Madrid	Spain	1
Hospital Universitario 12 de Octubre	Madrid	Spain	359
Hospital Universitario de A Coruña	A Coruña	Spain	3
Hospital Universitario Insular de Gran Canaria	Las Palmas de Gran Canaria	Spain	6
Hospital Universitario Ramon y Cajal	Madrid	Spain	141
Hospital Universitario Vall D'Hebron	Barcelona	Spain	86
Hospital Virgen de la Victoria de Malaga	Málaga	Spain	1
Institut Bergonié	Bordeaux	France	47
Institut Gustave Roussy	Paris	France	9
IRCCSS AOU Bologna	Bologna	Italy	1
Istituto Nazionale Tumori Regina Elena	Roma	Italy	5

Clinical trials